Carfilzomib
- Generic Name
- Carfilzomib
- Brand Names
- Kyprolis
- Drug Type
- Small Molecule
- Chemical Formula
- C40H57N5O7
- CAS Number
- 868540-17-4
- Unique Ingredient Identifier
- 72X6E3J5AR
- Background
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
- Indication
Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.
- Associated Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 47
- Registration Number
- NCT02969837
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸NorthShore University Health System, Evanston, Illinois, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
High Dose Carfilzomib for Newly Diagnosed Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT02937571
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 120
- Registration Number
- NCT02899052
- Locations
- 🇺🇸
Oncology Hematology Associates (OHA) - Springfield /ID# 218855, Springfield, Missouri, United States
🇺🇸University of Pennsylvania /ID# 151768, Philadelphia, Pennsylvania, United States
🇺🇸University of Texas Southwestern Medical Center /ID# 218336, Dallas, Texas, United States
Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Target Recruit Count
- 124
- Registration Number
- NCT02891811
- Locations
- 🇦🇹
Bezirkskrankenhaus Kufstein, Innere Medizin, Interne II u. onkologische Tagesklinik, Kufstein, Austria
🇦🇹Univ.Klinikum Krems, Klin. Abt. f. Innere Medizin 2, Mitterweng, Austria
🇦🇹Ordensklinikum Linz - Elisabethinen, I. Interne Abt. Haemato-Onkologie, Linz, Austria
Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma
- Conditions
- Lymphoma, Non-hodgkinHodgkin Disease
- Interventions
- First Posted Date
- 2016-08-16
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 14
- Registration Number
- NCT02867618
- Locations
- 🇺🇸
Columbia University Irving Medical Center - Center for Lymphoid Malignancies, New York, New York, United States
Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat
- Conditions
- Multiple Myeloma
- Interventions
A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2016-05-16
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 466
- Registration Number
- NCT02773030
- Locations
- 🇺🇸
Local Institution - 101, Atlanta, Georgia, United States
🇺🇸Local Institution - 108, Hackensack, New Jersey, United States
🇺🇸Local Institution - 115, Boston, Massachusetts, United States
Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2016-11-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT02756663
Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2016-01-20
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 180
- Registration Number
- NCT02659293
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Wayne State University - Karmanos Cacner Institute, Detroit, Michigan, United States
🇵🇱Polish Myeloma Consortium, Poznań, Poland
Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2015-12-11
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Registration Number
- NCT02628704
- Locations
- 🇺🇸
James R. Berenson MD, Inc, West Hollywood, California, United States
🇺🇸Waverly Hematology, Cary, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.